$2.14
+0.08 (+3.88%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where DWTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 2 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC) · FINRA short interest 1.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic PainNCT06848348NRS PainRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Halneuron, Placebo, Halneuron (Open Label Extension) | Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain | 240 | Jul 2026 | 2026-05-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19